SPRCY SciSparc Ltd Sponsored ADRs

SciSparc Ltd., a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. Its drug development programs include SCI-110, which has completed Phase II a clinical trial for the treatment of Tourette syndrome and Obstructive Sleep Apnea; THX-160, which has completed two preliminary preclinical studies for the treatment of acute and chronic pain; and THX-210 for the treatment of autism spectrum disorder and epilepsy. SciSparc Ltd. has a collaboration with The University of Calgary to evaluate the analgesic effect of Therapix's CB2R agonist proprietary drug candidate, THX-160; and an agreement with Procaps to develop and commercially manufacture SCI-110, as well as CannAmide, a palmitoylethanolamide compound in softgel capsule form. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in February 2021. SciSparc Ltd. was founded in 2004 and is based in Ramat Gan, Israel.

This security is traded over-the-counter, or OTC. We don't always have accurate pricing data on OTC stocks.

$6.25    OTCQB
As of 07/26/2021     OTCMarkets

Security Information
Category1:  US Equity
Category2:  ADRs
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  Israel
Country of incorporation:  
IPO date:  03/21/2021
Outstanding shares:  2,032,510
Average volume:  4,871
Market cap:   $13,516,192
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   4.53
PS ratio:   0.00
Return on equity:   0.00%
Net income %:   0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy